Physician profile

James Michael Robison

General Practice (Dentist) · Rocklin, CA

NPI 1154798320

$241.96

in general payments reported to CMS, 2019-2025

6 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$88.38

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Dentsply Sirona INC $88.61 2021-2024 Astra Tech Implant System, Aquasil Ultra+ Digit Smart Wetting Impression Material, Cavitron
Ultradent Products INC $56.17 2022
Biohorizons Implant Systems INC. $52.17 2021-2022
Elevate Oral Care $18.41 2024 Fluorimax Mint, Advantage Arrest, Fluorimax 5000
Philips North America LLC $14.14 2023
Kulzer, LLC $12.46 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

James Michael Robison

$241.96

in general payments reported 2019-2025

Years
2021-2024
Top company
Dentsply Sirona INC

https://glasscript.com/doctor/1347174/james-michael-robison

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.